Cargando…
Duloxetine and Pregnancy Outcomes: Safety Surveillance Findings
Background: Duloxetine hydrochloride is approved for the treatment or management of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, chronic musculoskeletal pain, and fibromyalgia in the United States. These conditions affect millions of women, including...
Autores principales: | Hoog, Sharon L, Cheng, Yingkai, Elpers, John, Dowsett, Sherie A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590601/ https://www.ncbi.nlm.nih.gov/pubmed/23471302 http://dx.doi.org/10.7150/ijms.5213 |
Ejemplares similares
-
Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study
por: Huybrechts, Krista F, et al.
Publicado: (2020) -
Duloxetine hydrochloride
por: Bhadbhade, Mohan, et al.
Publicado: (2009) -
Safety findings from Phase 3 lasmiditan studies for acute treatment
of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019) -
The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity
por: Wise, T N, et al.
Publicado: (2007) -
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
por: Loo, Li Shen, et al.
Publicado: (2019)